Incorrect identification of recent HIV infection in adults in the United States using a limiting-antigen avidity assay

AIDS

Volumn 28, Issue 8, 2014, Pages 1227-1232

  Longosz, Andrew F ^a   Mehta, Shruti H ^b   Kirk, Gregory D ^b   Margolick, Joseph B ^b   Brown, Joelle ^c   Quinn, Thomas C ^a,d   Eshleman, Susan H ^d   Laeyendecker, Oliver ^a,d  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HIV; Incidence; Limiting antigen avidity; Misclassification; MSM; People who inject drugs

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; DIAGNOSTIC ERROR; DISEASE MISCLASSIFICATION; FEMALE; GENDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIMITING ANTIGEN AVIDITY ASSAY; MAJOR CLINICAL STUDY; MALE; OPTICAL DENSITY; PRIORITY JOURNAL; RACE; SEROCONVERSION; UNITED STATES; VIRUS LOAD; ANTIBODY AFFINITY; CLINICAL TRIAL; HIV INFECTIONS; IMMUNOASSAY; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; YOUNG ADULT;

ADULT; AGED; ANTIBODY AFFINITY; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOASSAY; INCIDENCE; MALE; MIDDLE AGED; UNITED STATES; VIRAL LOAD; YOUNG ADULT;

EID: 84927909977     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000221     Document Type: Article

References (30)

1. Duong YT, Qiu M, De AK, Jackson K, Dobbs T, Kim AA, et al. Detection of recent HIV-1 infection using a new limitingantigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies. PLoS One 2012; 7:e33328.
2. Wei X, Liu X, Dobbs T, Kuehl D, Nkengasong JN, Hu DJ, et al. Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein. AIDS Res Hum Retroviruses 2010; 26:61-71.
3. Frieden T. Remarks from the Director of the US Centers for Disease Control and Prevention. In Conference on Retroviruses and Opportunistic Infections. Atlanta, Georgia; 2013.
4. New Test Raises Hopes in Global HIV/AIDS Fight. In The Wall Street Journal. Dow Jones & Company, Inc.; 2012.
5. UNAIDS. WHO/UNAIDS technical update on HIV incidence assays for surveillance and epidemic monitoring. Geneva, Switzerland; 2013.
6. Konikoff J, Brookmeyer R, Longosz AF, Cousins MM, Celum C, Buchbinder SP, et al. Performance of a limitingantigen avidity enzyme immunoassay for cross-sectional estimation of HIV incidence in the United States. PLoS One 2013; 8:e82772.
7. Welte A, McWalter TA, Laeyendecker O, Hallett TB. Using tests for recent infection to estimate incidence: problems and prospects for HIV. Euro Surveill 2010; 15:pii19589.
8. Dobbs T, Kennedy S, Pau CP, McDougal JS, Parekh BS. Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion. J Clin Microbiol 2004; 42:2623-2628.
9. Longosz AF, Serwadda D, Nalugoda F, Kigozi G, Franco V, Gray RH, et al. Impact of HIV subtype on performance of the limiting antigen-avidity enzyme immunoassay, the Bio-Rad avidity assay, and the BED capture immunoassay in Rakai, Uganda. AIDS Res Hum Retroviruses 2013 (in press).
10. Laeyendecker O, Brookmeyer R, Cousins MM, Mullis CE, Konikoff J, Donnell D, et al. HIV incidence determination in the United States: A multiassay approach. J Infect Dis 2013; 207:232-239.
11. Mullis CE, Munshaw S, Grabowski MK, Eshleman SH, Serwadda D, Brookmeyer R, et al. Differential specificity of HIV incidence assays in HIV subtypes A and D-infected individuals from Rakai, Uganda. AIDS Res Hum Retroviruses 2013; 29:1146-1150.
12. Laeyendecker O, Brookmeyer R, Mullis CE, Donnell D, Lingappa J, Celum C, et al. Specificity of four laboratory approaches for cross-sectional HIV incidence determination: Analysis of samples from adults with known nonrecent HIV infection from five African countries. AIDS Res Hum Retroviruses 2012; 28:1177-1183.
13. Barnighausen T, McWalter TA, Rosner Z, Newell ML, Welte A. HIV incidence estimation using the BED capture enzyme immunoassay: Systematic review and sensitivity analysis. Epidemiology 2010; 21:685-697.
14. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2010. Geneva, Switzerland: UNAIDS; 2010.
15. Hayashida T, Gatanaga H, Tanuma J, Oka S. Effects of low HIV type 1 load and antiretroviral treatment on IgG-capture BEDenzyme immunoassay. AIDS Res Hum Retroviruses 2008; 24:495-498.
16. Laeyendecker O, Brookmeyer R, Oliver AE, Mullis CE, Eaton KP, Mueller AC, et al. Factors associated with incorrect identification of recent HIV infection using the BED capture immunoassay. AIDS Res Hum Retroviruses 2012; 28:816-822.
17. Marinda ET, Hargrove J, Preiser W, Slabbert H, van Zyl G, Levin J, et al. Significantly diminished long-term specificity of the BED capture enzyme immunoassay among patients with HIV-1 with very low CD4 counts and those on antiretroviral therapy. J Acquir Immune Defic Syndr 2010; 53:496-499.
18. Hladik W, Olara D, Mermin J, Moore D, Were W, Alexander L, et al. Effect of CD4R T cell count and antiretroviral treatment on two serological HIV incidence assays. AIDS Res Hum Retroviruses 2012; 28:95-99.
19. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR Jr. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987; 126:310-318.
20. Galai N, Safaeian M, Vlahov D, Bolotin A, Celentano DD, Study A. Longitudinal patterns of drug injection behavior in the ALIVE Study cohort, 1988-2000: Description and determinants. Am J Epidemiol 2003; 158:695-704.
21. Laeyendecker O, Oliver A, Astemborski J, Owen SM, Kirk G, Mehta S, et al. Improved precision of cross-sectional HIV incidence testing using a multiassay algorithm that includes BED and an avidity assay with modified assay cut-offs. In 18th Conference on Retroviruses and Opportunistic Infections (abstract #935). San Francisco, CA; 2010.
22. Suligoi B, Rodella A, Raimondo M, Regine V, Terlenghi L, Manca N, et al. Avidity Index for anti-HIV antibodies: comparison between third- And fourth-generation automated immunoassays. J Clin Microbiol 2011; 49:2610-2613.
23. Barin F, Meyer L, Lancar R, Deveau C, Gharib M, Laporte A, et al. Development and validation of an immunoassay for identification of recent human immunodeficiency virus type 1 infections and its use on dried serum spots. J Clin Microbiol 2005; 43:4441-4447.
24. Marzinke MA, Clarke W, Wang L, Cummings V, Liu TY, Piwowar-Manning E, et al. Nondisclosure of HIV status in a clinical trial setting: Antiretroviral drug screening can help distinguish between newly-diagnosed and previously-diagnosed HIV infection. Clin Infect Dis 2014; 58:117-120.
25. Fogel JM, Wang L, Parsons TL, Ou SS, Piwowar-Manning E, Chen Y, et al. Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). J Infect Dis 2013; 208:1624-1628.
26. Sullivan AK, Savage EJ, Lowndes CM, Paul G, Murphy G, Carne S, et al. Nondisclosure of HIV status in UK sexual health clinics: A pilot study to identify nondisclosure within a national unlinked anonymous seroprevalence survey. Sex Transm Infect 2013; 89:120-121.
27. Kahle EM, Kashuba A, Baeten JM, Fife KH, Celum C, Mujugira A, et al. Unreported antitretroviral use by HIV-1 infected participants enrolling in a prospective research study. J Acquir Immune Defic Syndr 2014; 65:e90-e94.
28. Laeyendecker O, Piwowar-Manning E, Fiamma A, Kulich M, Donnell D, Bassuk D, et al. Estimation of HIV incidence in a large, community-based, randomized clinical trial: NIMH project accept (HIV Prevention Trials Network 043). PLoS One 2013; 8:e68349.
29. Wendel SK, Mullis CE, Eshleman SH, Blankson JN, Moore RD, Keruly JC, et al. Effect of natural and ARV-induced viral suppression and viral breakthrough on anti-HIV antibody proportion and avidity in patients with HIV-1 subtype B infection. PLoS One 2013; 8:e55525.
30. Cousins MM, Konikoff J, Laeyendecker O, Celum C, Buchbinder SP, Seage GR 3rd, et al. HIV diversity as a biomarker for HIV incidence estimation: Including a high resolution melting diversity assay in a multiassay algorithm. J Clin Microbiol 2014; 52:115-121.